📰 Array Biopharma News
Page 6 - Array Biopharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Array Biopharma. Real-time updates on events, politics, business and more.
February 3, 2023
Assuming an upward rerating, PFE could hit our price target of $55.79, suggesting 27.40% upside potential from current levels. Click here to read our analysis.
January 6, 2023
Pfizer (PFE) on Thursday told employees that it is lifting early-stage research into rare diseases and externalize this, according to Barron's.
December 23, 2022
Investors should steer clear of Deciphera shares. Read why the risk/reward profile does not look attractive at this time.
November 20, 2022
Eli Lilly’s stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage clinical trials. While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.
November 3, 2022
WATERTOWN, Mass., Nov. 03, 2022 -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader... | November 3, 2022
November 3, 2022
WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...
September 14, 2022
Leadership Team Continues to Expand with Addition of Key Leader in Clinical OperationsMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appoint...